Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Medical IT legislation

This article was originally published in The Gray Sheet

Executive Summary

"Health Technology to Enhance Quality Act of 2005," introduced June 16 by Senate Majority Leader Bill Frist (R-Tenn.) and Sen. Hillary Clinton (D-N.Y.), would codify the Office of National Coordinator for Information Technology, announced by the Administration in April 2004, and establish standards to guide the design and implementation of interoperable health information systems. The bill extends healthcare providers a "narrow" safe harbor from federal Stark self-referral and anti-kickback laws in cases where such leeway is advantageous to facilitate health IT adoption, and directs HHS to devise guidelines to permit health plans and providers to share in savings that result from adopting health IT. On the house side, Reps. Tim Murphy (R-Penn.) and Patrick Kennedy (D-R.I.) have introduced "The 21 Century Health Information Act" (HR 2234) (1"The Gray Sheet" June 6, 2005, p.11)...

You may also be interested in...

AdvaMed Outlines HealthCare IT Priorities As Senate Prepares Legislation

Healthcare information technology legislation should create rewards for new technologies and services that improve quality and reduce patient care costs, according to AdvaMed

Finance Watch: Silverback, Kinnate, Sigilon Launch December’s First IPOs

Public Company Edition: Lixte’s small uplisting was the only biopharma initial public offering in the US during Thanksgiving week, but IPOs are ramping up again. Also, LifeSci launched its second SPAC and in follow-on offerings Reata brought in $281m and Intellia grossed $175m.

BioCryst’s Oral Option To Take On Injectables In HAE Prophylaxis Market

Orladeyo is the first oral prophylactic approved in the US for hereditary angioedema, with Japan and EU approvals expected to follow. Pricing of $485,000 a year undercuts segment leader.




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts